Skip to main content
. 2016 Apr 11;11(4):e0153217. doi: 10.1371/journal.pone.0153217

Fig 2. Cumulative incidence of tuberculosis in RA patients, who received therapy with csDMARDs, etanercept, adalimumab or rituximab, in comparison with non-RA subjects.

Fig 2

csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs.